Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
|
|
Zyla Life Sciences (ZCOR)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/20/2020 |
8-K
| Investor presentation|
Docs:
|
"Assertio Completed Merger with Zyla Life Sciences Trading under ASRT on Nasdaq Global Select Market Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million 1 Upwards of $40 million in Expected Cost Synergies LAKE FOREST, Ill., -- Assertio Holdings, Inc., the successor issuer to Assertio Therapeutics, Inc., announced the closing of the merger with Zyla Life Sciences. The combined company will operate under the Assertio name and trade on Nasdaq under the ticker ASRT. The merger creates a growing commercial pharmaceutical company with neurology, inflammation and pain products. The Company now has a differentiated portfolio of non-steroidal anti-inflammatory drugs commonly used by neurologists, orthopedic surgeons, internists, women’ s health providers, podiatrists, p...",
"Presentation by Assertio Holdings, Inc." |
|
| 05/20/2020 |
8-K
| Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa...|
Docs:
|
"Agreement and Plan of Merger, by and among Zyla Life Sciences, Alligator Zebra Holdings, Inc., Assertio Therapeutics, Inc., Zebra Merger Sub, Inc. and Alligator Merger Sub, Inc. (Certain schedules (or similar attachments) to the Agreement and Plan of Merger have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant agrees to furnish copies of any such schedules (or similar attachments) to the U.S. Securities and Exchange Commission or its staff upon request.)",
"Fifth Amended and Restated Certificate of Incorporation of Zyla Life Sciences",
"Third Amended and Restated Bylaws of Zyla Life Sciences" |
|
| 05/15/2020 |
8-K
| Quarterly results |
| 05/15/2020 |
8-K
| Quarterly results |
| 04/13/2020 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/27/2020 |
8-K
| Quarterly results |
| 03/17/2020 |
8-K
| Quarterly results |
| 01/28/2020 |
8-K
| Entry into a Material Definitive Agreement, Other Events |
| 01/13/2020 |
8-K
| Investor presentation |
| 12/19/2019 |
8-K
| Quarterly results |
| 11/14/2019 |
8-K
| Quarterly results |
| 10/30/2019 |
8-K
| Quarterly results |
| 10/23/2019 |
8-K
| Quarterly results |
| 08/30/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/13/2019 |
8-K
| Quarterly results |
| 08/01/2019 |
8-K
| Entry into a Material Definitive Agreement |
| 06/20/2019 |
8-K
| Appointed a new director|
Docs:
|
"Zyla Life Sciences Appoints Dr. Gary M. Phillips to Board of Directors WAYNE, Pa.—June 19, 2019 Zyla Life Sciences , a growing commercial-stage life sciences company, announced the appointment of Gary M. Phillips, M.D. to its board of directors. “Gary brings to Zyla a wealth of experience from working in the pharmaceutical industry in a range of commercial, business development, strategy and clinical development leadership positions,” said Timothy P. Walbert, Zyla chairman of the board and chairman, president and chief executive officer of Horizon Therapeutics. “With our focus on driving commercial growth at Zyla, Gary's commercial experience will be helpful.” Over the past two decades, Dr. Phillips has worked in leadership roles at life sciences and pharmaceutical companies. He currently ..." |
|
| 06/06/2019 |
8-K
| Resignation/termination of a director |
| 05/16/2019 |
8-K
| Quarterly results |
| 05/03/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 04/17/2019 |
8-K
| Quarterly results |
| 04/16/2019 |
8-K/A
| Quarterly results |
| 04/01/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/20/2019 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 02/01/2019 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and ...|
Docs:
|
"Fourth Amended and Restated Certificate of Incorporation of Egalet Corporation",
"Second Amended and Restated Bylaws of Egalet Corporation",
"Indenture, among the Company, the Guarantors from time to time party thereto and U.S. Bank National Association, as trustee and collateral agent",
"Promissory Note, by and between Egalet Corporation and Iroko Pharmaceuticals Inc",
"Form of Iroko Warrant Agreement",
"Form of Non-Iroko Warrant Agreement",
"Form of Royalty Rights Agreement",
"Collateral Agreement, among the Company, the Subsidiary Parties from time to time party thereto and U.S. Bank National Association as trustee and collateral agent",
"Stockholders' Agreement, among the Company and the stockholder(s) of the Company from time to time party thereto",
"Form of Preemptive Rights Agreement" |
|
| 02/01/2019 |
8-K
| Amended existing or entered into new employment agreement with an officer|
Docs:
|
"Fourth Amended and Restated Certificate of Incorporation of Egalet Corporation",
"Second Amended and Restated Bylaws of Egalet Corporation",
"Indenture, among the Company, the Guarantors from time to time party thereto and U.S. Bank National Association, as trustee and collateral agent",
"Promissory Note, by and between Egalet Corporation and Iroko Pharmaceuticals Inc",
"Form of Iroko Warrant Agreement",
"Form of Non-Iroko Warrant Agreement",
"Form of Royalty Rights Agreement",
"Collateral Agreement, among the Company, the Subsidiary Parties from time to time party thereto and U.S. Bank National Association as trustee and collateral agent",
"Stockholders' Agreement, among the Company and the stockholder(s) of the Company from time to time party thereto",
"Form of Preemptive Rights Agreement" |
|
| 01/16/2019 |
8-K
| Bankruptcy or Receivership, Financial Statements and Exhibits |
| 01/07/2019 |
8-K
| Quarterly results |
| 11/19/2018 |
8-K
| Quarterly results |
| 11/13/2018 |
8-K
| Investor presentation |
| 10/31/2018 |
8-K
| Acquisition/merger/asset purchase announced|
Docs:
|
"Asset Purchase Agreement, by and among Egalet Corporation, Egalet US Inc. and Iroko Pharmaceuticals Inc",
"Restructuring Support Agreement, by and among Egalet Corporation, Egalet US Inc., Egalet Limited and the Supporting Noteholders",
"Employment Separation Agreement and General Release, by and among Egalet Corporation and Stanley J. Musial",
"Termination and Settlement Agreement, by and among Halo Pharmaceutical Inc., Egalet Corporation, Egalet US Inc. and Egalet Ltd",
"Debtors' Joint Plan of Reorganization, filed with the Court on October 30, 2018",
"Disclosure Statement for Debtors' Joint Plan of Reorganization, filed with the Court on October 30, 2018",
"Egalet Signs Asset Purchase Agreement to Acquire Four FDA-Approved, Non-Narcotic Pain Products" |
|
| 10/25/2018 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 10/22/2018 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 10/18/2018 |
8-K
| Quarterly results |
|
|
|